Non Small Cell Lung Cancer Treatment Algorithm

Postoperative radiotherapy in non small cell lung cancer.

Non small cell lung cancer treatment algorithm.

This guideline covers diagnosing and managing non small cell and small cell lung cancer. Non small cell lung cancer t3 n0 stage iib bronchoscopy mediastinoscopy or endobronchial ultrasound fine needle aspiration ebus fna brain mri for symptomatic patients t1 2 n0 pulmonary function tests pathology 1 consistent with non small cell lung cancer history and physical chest x ray laboratory studies to. Small cell lung cancer sclc is an aggressive malignancy. It primarily develops in older adult smokers.

The treatment options for non small cell lung cancer nsclc are based largely on the stage extent of the cancer. Early and locally advanced non small cell lung cancer metastatic non small cell lung cancer thymic epithelial tumours malignant pleural mesothelioma small cell lung cancer. Surgery is potentially the most curative therapeutic option for this disease. In non small cell lung cancer nsclc results of standard treatment are poor except for the most localized cancers.

But other factors such as a person s overall health and lung function and if the cancer cells have certain gene or protein changes can also be important. Treatment recommended for some patients in selected patient group. Esmo has clinical practice guidelines on the following lung and chest tumours. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used and that people have access to suitable palliative care and follow up.

All newly diagnosed patients with nsclc are potential candidates for studies evaluating new forms of treatment. Radiotherapy should be considered for high risk patients with stage ii disease positive or close margins lymph node involvement in the mediastinum and or extracapsular extension. The previous standard of care in metastatic non small cell lung cancer nsclc was to treat patients with a platinum doublet for four to six cycles and to offer second line therapy upon progression the emergence of molecular testing specifically for the epidermal growth factor receptor egfr and for anaplastic lymphoma kinase alk enables us to better tailor. Approximately two thirds of patients have evidence of distant metastasis at presentation.

Cancer treatment algorithms depict best practices for care delivery that illustrate a multidisciplinary approach for evaluating diagnosing and providing treatment recommendations and ongoing surveillance for various malignancies.